Overview

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Status:
Active, not recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Collaborators:

Breast International Group
Genentech, Inc.

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cyclophosphamide
Docetaxel
Doxorubicin
Epirubicin
Fluorouracil
Liposomal doxorubicin
Paclitaxel
Pertuzumab
Trastuzumab